Daniel G. Anderson, Akin Akinc, Naushad Hossain, Robert Langer 

Slides:



Advertisements
Similar presentations
Volume 8, Issue 2, Pages (August 2003)
Advertisements

Volume 12, Issue 6, Pages (December 2005)
414. A Novel Clinical Severity Scoring Measure in Canine X-Linked Myotubular Myopathy: Results Following Systemic AAV Gene Replacement    Molecular Therapy 
209. Use of Helicobacter pyroli Neutrophil Activating Protein (NAP) as an Immune- Modulatory Agent To Enhance the Efficacy of Oncolytic Adenovirus Therapy.
Man's Best Friend: Utilizing Naturally Occurring Tumors in Dogs to Improve Chimeric Antigen Receptor T-cell Therapy for Human Cancers  Melinda Mata, Stephen.
Engineering Natural Killer Cells for Cancer Immunotherapy
Genome-editing Technologies for Gene and Cell Therapy
627. Non-Invasive, Multimodal Imaging of Microvesicles with Metabolically Biotinylated, Membrane-Bound Gaussia Luciferase    Molecular Therapy  Volume.
Elizabeth Morris, Alex Scibetta, Aiping Lu, Xueqin Gao, Johnny Huard
162. Stability of Polymer/Plasmid DNA Complexes In Vitro and In Vivo
281. Rapid Generation of Induced Pluripotent Stem Cells (iPSCs) from the Urine of a Patient with Duchenne Muscular Dystrophy    Molecular Therapy  Volume.
Hydrodynamic Gene Delivery: Its Principles and Applications
Direct Conversion of Skin Cells into Blood: Alchemy or Science?
Molecular Therapy  Volume 20, Pages S261-S262 (May 2012) DOI: /S (16)
Volume 10, Issue 4, Pages (October 2004)
Evolving Gene Therapy in Primary Immunodeficiency
343. Benchtop DNA Synthesizer: Oligo-Templated Polymerization (OTP)
Engineering Natural Killer Cells for Cancer Immunotherapy
637. Effect of PEG Grafting Degree on Morphology and Transfection Efficiency of Polycation-g-PEG/DNA Nanoparticles    Molecular Therapy  Volume 20, (May.
Escaping the Valley of Death
Volume 10, Issue 1, Pages (July 2004)
Volume 8, Issue 3, Pages (September 2003)
Volume 26, Issue 2, Pages (February 2018)
HIV Receives a “One Two Knockout Punch”
Volume 25, Issue 1, Pages 5-7 (January 2017)
A Theranostic “SMART” Aptamer for Targeted Therapy of Prostate Cancer
Volume 9, Issue 4, Pages (April 2004)
Volume 10, Issue 2, Pages (August 2004)
Volume 25, Issue 5, Pages (May 2017)
724. Blood-Derived Endothelial Progenitor Cells Can Be Isolated With a Novel Method of Diluted Whole Blood Incubation with AMD3100-Induced Mobilization.
Molecular Therapy  Volume 20, (May 2012) DOI: /S (16)
VSV-G Envelope Glycoprotein Forms Complexes with Plasmid DNA and MLV Retrovirus-like Particles in Cell-free Conditions and Enhances DNA Transfection 
Volume 19, Issue 9, Pages (September 2011)
Genome-editing Technologies for Gene and Cell Therapy
Premal Lulla, Carlos A. Ramos  Molecular Therapy 
Daniel G. Anderson, Akin Akinc, Naushad Hossain, Robert Langer 
Molecular Therapy  Volume 20, (May 2012) DOI: /S (16)
Molecular Therapy  Volume 7, Issue 5, (May 2003) DOI: /S (16)
847. Eradication of Therapy-Resistant Human Prostate Tumors Using an Ultrasound Guided Site-Specific Cancer Terminator Virus Delivery Approach    Molecular.
Designer Lipids Advance Systemic siRNA Delivery
Volume 25, Issue 5, Pages (May 2017)
Donna M. Martin, Yehoash Raphael  Molecular Therapy 
133. Survival with Normal Neurological Development of the Juvenile Lethal Urea Cycle Defect Arginase Deficient Mouse with AAV Gene Therapy    Molecular.
660. Bowel/Bladder Sensation and Control in Patients with Spinal Cord Injury Treated with Human Embryonic Stem Cell Therapy  Geeta Shroff  Molecular Therapy 
Volume 26, Issue 2, Pages (February 2018)
68. Site Specific Intra-Placental Gene Transfer Corrects Fetal Growth Restriction in a Novel Mouse Model of Placental Insufficiency (PI)    Molecular.
521. Multiplex Genome Editing of TCR°/CD52 Genes as a Platform for “Off the Shelf” Adoptive T-Cell Immunotherapies    Molecular Therapy  Volume 22, Pages.
Objective tinnitus resulting from internal carotid artery stenosis
What Does It Take to Bind CAR?
335. High Content Analysis Platform for Optimization of Lipid Mediated CRISPR-Cas9 Delivery Strategies in Human Cells  Benjamin Steyer, Jared Carlson-Stevermer,
Volume 10, Issue 4, Pages (October 2004)
Volume 26, Issue 4, Pages (April 2018)
Nerve Growth Factor Receptor-Mediated Gene Transfer
674. Molecular, Biochemical and Biomechanical Analysis of Articular Cartilage Repaired with Genetically Modified Chondrocytes Expressing Insulin-Like.
Molecular Therapy  Volume 18, Pages S260-S261 (May 2010) DOI: /S (16)
In This Issue Molecular Therapy Volume 16, Issue 4, (April 2008)
Ajay Gautam, Charles L. Densmore, J.Clifford Waldrep  Molecular Therapy 
372. Targeted Mutagenesis of Ubiquitin-Binding Lysine Residues on the Adeno- Associated Virus (AAV)2 Capsid Improves Its Transduction Efficiency    Molecular.
521. AAV Immunotherapy Induces Functional Antigen Specific Regulatory T-Cells to a Neuroantigen: A Potential Treatment for MS  Brad E. Hoffman  Molecular.
Volume 10, Issue 2, Pages (August 2004)
Rajendra N. Mitra, Min Zheng, Zongchao Han
740. Prevention of Radiation-Induced Lung Injury by Administration of Gene-Modified Mesenchymal Stem Cells    Molecular Therapy  Volume 20, Pages S285-S286.
Molecular Therapy  Volume 21, Pages S247-S248 (May 2013)
Vanadium: A Panacea for Resistance to Oncolytic Immunotherapy?
Shigeki Yagyu, Malcolm K. Brenner
86. A Highly Compact Epitope-Based Marker Suicide Gene for Safer and Easier Adoptive T-Cell Gene Therapy    Molecular Therapy  Volume 20, Pages S35-S36.
Intracytoplasmic delivery of anionic proteins
Zhijian Wu, Aravind Asokan, R. Jude Samulski  Molecular Therapy 
Shirley Wong, Roderick A. Slavcev
624. Randomized Phase II Trial of Adjuvant Autologous Tumor Cell Vaccine (FANG™) for High Risk Stage III/IV Ovarian Cancer: Preliminary Results    Molecular.
Presentation transcript:

Structure/property studies of polymeric gene delivery using a library of poly(β-amino esters)  Daniel G. Anderson, Akin Akinc, Naushad Hossain, Robert Langer  Molecular Therapy  Volume 11, Issue 3, Pages 426-434 (March 2005) DOI: 10.1016/j.ymthe.2004.11.015 Copyright © 2004 The American Society of Gene Therapy Terms and Conditions

Fig. 1 Acrylate and amino monomers used to synthesize poly(β-amino ester) library. Molecular Therapy 2005 11, 426-434DOI: (10.1016/j.ymthe.2004.11.015) Copyright © 2004 The American Society of Gene Therapy Terms and Conditions

Fig. 2 Molecular weight of polymer library. Mean polymer molecular weights organized from best transfecting (left) to worst (right) and amine/acrylate ratio from high (front) to low (back). Molecular weight was measured by GPC relative to polystyrene standards. Red arrows indicate polymers made with DMSO as described under Experimental Procedures. Molecular Therapy 2005 11, 426-434DOI: (10.1016/j.ymthe.2004.11.015) Copyright © 2004 The American Society of Gene Therapy Terms and Conditions

Fig. 3 Transfection proficiency of the polymer library. COS-7 cells were transfected with polymer/DNA complexes at six polymer/DNA ratios in quadruplicate: 10:1, 20:1, 30:1, 40:1, 60:1, and 100:1. The average transfection level in nanograms of luciferase per well of the optimal polymer/DNA ratio is presented. Polymers are organized from highest transfecting (C32) to lowest transfecting (II32) and amine/acrylate ratio from high (front) to low (back). Red arrows indicate polymers made with DMSO as described under Experimental Procedures. Molecular Therapy 2005 11, 426-434DOI: (10.1016/j.ymthe.2004.11.015) Copyright © 2004 The American Society of Gene Therapy Terms and Conditions

Fig. 4 Transfection proficiency relative to polymer molecular weight and polymer/DNA ratio. COS-7 cells were transfected with polymer/DNA complexes at six polymer/DNA ratios in quadruplicate: 10:1, 20:1, 30:1, 40:1, 60:1, and 100:1. The average transfection level in nanograms of luciferase per well is presented for all ratios as a function of molecular weight. Molecular Therapy 2005 11, 426-434DOI: (10.1016/j.ymthe.2004.11.015) Copyright © 2004 The American Society of Gene Therapy Terms and Conditions

Fig. 5 Relationship of polymer/DNA particle size and transfection efficiency. Polymer/DNA complexes were formed at polymer/DNA ratios optimal for transfection (Fig. 3). Data are organized from highest transfecting (left) to lowest transfecting (right) and amine/acrylate ratio from high (front) to low (back). Red arrows indicate polymers made with DMSO as described under Experimental Procedures. Molecular Therapy 2005 11, 426-434DOI: (10.1016/j.ymthe.2004.11.015) Copyright © 2004 The American Society of Gene Therapy Terms and Conditions

Fig. 6 Relationship of polymer/DNA complex surface charge and transfection efficiency. Polymer/DNA complexes were formed at polymer/DNA ratios optimal for transfection. ζ potential is presented in mV. Data are organized from highest transfecting (left) to lowest transfecting (right) and amine/acrylate ratio from high (front) to low (back). Red arrows indicate polymers made with DMSO as described under Experimental Procedures. Molecular Therapy 2005 11, 426-434DOI: (10.1016/j.ymthe.2004.11.015) Copyright © 2004 The American Society of Gene Therapy Terms and Conditions